Recobia Therapeutics and Gustave Roussy Transfert Join Forces to Bring Next-Generation Oncology Therapies Closer to Patients

Accelerate Innovation in Oncology Drug Delivery

Gustave Roussy Transfert's equity investment in Recobia Therapeutics reflects the institute's commitment to fostering breakthrough innovations that do not only improve care and treatment of cancer but also revolution quality of life for patients. As a world-renowned cancer treatment and research centre based in Paris, Gustave Roussy brings not only capital but also unparalleled clinical expertise, patient cohorts, and translational research capabilities.

This strategic partnership will enable Recobia Therapeutics to:

• Advance clinical validation of its SC delivery platform in a world-class oncology environment
• Access Gustave Roussy's network of internationally recognized oncologists and researchers
• Accelerate the development of SC formulations for leading ADC candidates
• Leverage Gustave Roussy's infrastructure for early-phase clinical trials and translational studies.

Vincent Gass, board member at Recobia Therapeutics, quotes: "Gustave Roussy's decision to invest in Recobia is a tremendous endorsement of our technology and our vision. Having one of Europe's foremost cancer institutions as a partner gives us both the scientific credibility and the clinical robustness we need to progress our pipeline and deliver on our promise to make new immunotherapies accessible to everyone and everywhere by revolutionizing the way they are administered."

Gustave Roussy Transfert echoed his enthusiasm. "Subcutaneous administration of biotherapies represents a major opportunity to enhance patient comfort, reduce hospital burden, and improve treatment adherence. Recobia's hydrogel platform addresses a critical unmet need and we are proud to support its development as both a scientific partner and an investor," added Christophe Javaud, Executive Director at Gustave Roussy Transfert.
 
Background: The Case for Subcutaneous Oncology Delivery

Most oncology biotherapies, including monoclonal antibodies and the rapidly growing class of ADCs, are currently administered intravenously (IV), requiring lengthy infusion sessions in hospital or clinic settings. SC administration offers compelling clinical and economic advantages, including shorter administration time, patient self-injection potential, and reduced healthcare resource utilization.

Recobia Therapeutics’s proprietary platform is designed to overcome the key formulation and delivery barriers that have historically limited SC administration of biologics and particularly ADCs, positioning the company at the forefront of this emerging paradigm shift in oncology care.